Galmed Pharmaceuticals (NASDAQ:GLMD) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research report released on Tuesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Stock Up 3.8 %

Shares of NASDAQ:GLMD opened at $1.91 on Tuesday. Galmed Pharmaceuticals has a 12-month low of $1.75 and a 12-month high of $23.80. The stock has a market cap of $1.23 million, a PE ratio of -0.11 and a beta of 0.66. The business has a 50 day moving average of $2.71 and a 200-day moving average of $3.54.

Institutional Investors Weigh In On Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC purchased a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned approximately 3.97% of Galmed Pharmaceuticals at the end of the most recent quarter. 76.14% of the stock is currently owned by hedge funds and other institutional investors.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.